Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe

Pharmacogenetics

Volumn 8, Issue 1, 1998, Pages 55-66

  Hughes, Nicola C ^a   Janezic, Susan A ^a   McQueen, Karina L ^a   Jewett, Michael A S ^b   Castranio, Trisha ^c   Bell, Douglas A ^c   Grant, Denis M ^a  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Acetyltransferase; Allelic variants; NAT1; Pharmacogenetics

Indexed keywords

ACYLTRANSFERASE; AMINOSALICYLIC ACID;

ACETYLATION; ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME ACTIVITY; FEMALE; GENE LOCUS; GENETIC VARIABILITY; HUMAN; HUMAN EXPERIMENT; MALE; MISSENSE MUTATION; MOLECULAR CLONING; NONSENSE MUTATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; URINALYSIS; URINE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; BASE SEQUENCE; CLONING, MOLECULAR; DNA PRIMERS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; KINETICS; MALE; MIDDLE AGED; P-AMINOSALICYLIC ACID; PHENOTYPE; POLYMERASE CHAIN REACTION; VARIATION (GENETICS);

EID: 0031932385     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199802000-00008     Document Type: Article

References (36)

1. Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH, Kadlubar FF, Lucier GW. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993; 14, 1689-1692.
2. Bell DA, Badawi AF, Lang NP, Ilett KF, Kadlubar FF, Hirvonen A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 1995a; 55, 5226-5299.
3. Bell DA, Stephens EA, Castranio T, Umbach DM, Watson M, Deakin M, Elder J, Hendrickse C, Duncan H, Strange RC. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res 1995b; 55, 3537-3542.
4. Blum M, Grant DM, McBride OW, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization and functional expression. DNA Cell Biol 1990; 9, 193-203.
5. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Prof Nat Acad Sci USA 1991; 88, 5237-5241.
6. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72, 248-254.
7. Cribb AE, Grant DM, Miller MA, Speilberg SP. Expression of monomorphic arylamine N-acetyltransferase (NAT1) in human leukocytes. J Pharmacol Exp Therap 1991; 259, 1241-1246.
8. Deguchi T, Mashimo M, Suzuki T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J Biol Chem 1990; 265, 12757-12760.
9. Drayer DE, Stong JM, Jones B, Sandler A, Reidenberg MM. In vitro acetylation of drugs by human blood cells. Drug Metab Dispos 1974; 2, 499-505.
10. 68 in the catalytic mechanism of polymorphic human NAT2. J Biol Chem 1992; 267, 7381-7385.
11. Dupret J-M, Goodfellow GH, Janezic SA, Grant DM. Structure-function studies of human arylamine N-acetyltransferases NAT1 and NAT2: functional analysis of NAT1/NAT2 protein chimeras expressed in E. coli. J Biol Chem 1994; 269, 26830-26835.
12. Evans DAP. N-acetyltransferase. Pharmacol Ther 1989; 42, 157-234.
13. Grant DM. Molecular genetics of the N-acetyltransferases. Pharmacogenetics 1993; 3, 45-50.
14. Grant DM, Meyer UA. Arylamine N-acetyltransferase. In: A. Haeberli, eds. Human protein data. Weinheim: VCH Verlagsges, 1993.
15. Grant UM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 1984; 17, 459-464.
16. Grant DM, Blum M, Demierre A, Meyer UA. Nucleolide sequence of an intronless gene for a human arylamine N-acetyltransferase related to polymorphic drug acetylation. Nucl Acids Res 1989; 17, 3978.
17. Grant DM, Mörike K, Eichelbaum M, Meyer UA. Acetylation pharmacogenetics: the slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest 1990; 85, 968-972.
18. Grant DM, Blum M, Beer M, Meyer UA. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 1991: 39, 184-191.
19. Grant DM, Vohra P, Avis Y, Ima A. Detection of a new polymorphism of human arylamine N-acetyltransferase NAT1 using p-aminosalicylic acid as an in vivo probe. J Basic Clin Physiol Pharmacol 1992: 3 (suppl.), 244.
20. Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, Yu-Plant VL, Grewal R. Human acetyltransferase polymorphisms. Mut Res 1997; 376, 61-70.
21. Hein DW, Ferguson RJ, Doll MA, Rustan TD, Gray K. Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes. Hum Mol Genet 1994; 3, 729-734.
22. Hickman D, Sim E. N-acetyltransferase polymorphism: comparison of phenotype and genotype in humans. Biochem Pharmacol 1991; 42, 1007-1014.
23. Hickman D, Risch A, Camilleri J, Sim E. Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants. Pharmacogenetics 1992: 2, 217-226.
24. Lindsay RM, Baty JD. Inter-individual variation of human blood N-acetyltransferase activity in vitro. Biochem Pharmacol 1988; 27, 3915-3921.
25. MacFerrin KD, Terranova MP, Schreiber SL, Verdine GL. Overproduction and dissection of proteins by the expression-cassette polymerase chain reaction. Proc Nat Acad Sci USA 1990; 87, 1937-1941.
26. Mandell GL, Sande MA. Drugs used in the chemotherapy of tuberculosis and leprosy. In: Gilman A, Goodman L, Rall T, Murads F, eds. The pharmacological basis of therapeutics. New York: MacMillan Publishing Co. 1985; 1208-1209.
27. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acids Res 1988; 16, 1215.
28. Ohsako S, Deguchi T. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. J Biol Chem 1990; 265, 4630-4634.
29. Sanger F, Nicklen S, Coulsen AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977; 74, 5463-5467.
30. Taylor JA, Umbach D, Stephens E, Paulson D, Robertson C, Mohler JL, Bell DA. Role of N-acetylation polymorphism at NAT1 and NAT2 in smoking-associated bladder cancer. Proc Am Assoc Cancer Res 1995; 36, 282.
31. USP DI. Drug Information for the Health Care Professional. Aminosalicylate sodium. Rockville, MD: United States Pharmacopeial Convention, Inc., 1991; 160-162.
32. Vatsis KP, Weber WW. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch Biochem Biophys 1993; 301, 71-76.
33. Vatsis KP, Weber WW, Bell DA, Dupret J-M, Price Evans DA, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995; 5, 1-17.
34. Ward A, Hickman D, Gordon J, Sim E. Arylamine N-acetyltransferase in human red blood cells. Biochem Pharmacol 1992; 44, 1099-1104.
35. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev 1985; 37, 25-79.
36. Weber WW, Vatsis KP. Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood. Pharmacogenetics 1993; 3, 209-212.